This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease
(AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 …

Introduction There is a tremendous need for identifying reliable blood-based biomarkers for
Alzheimer's disease (AD) that are tied to the biological ATN (amyloid, tau and …

Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early
changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels …

Background Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β
(Aβ) plaques, neurofibrillary tau tangles, and neurodegeneration in the brain parenchyma …

The relationship between neuroinflammation and cognition remains uncertain in early
Alzheimer's disease (AD). We performed a cross-sectional study to assess how …

Metabolic risk factors are associated with peripheral low-grade inflammation and an
increased risk for dementia. We evaluated if metabolic risk factors ie insulin resistance, body …

Background Elevated concentrations of low-density lipoprotein cholesterol (LDL-C) are
linked to dementia risk, and conversely, increased plasma concentrations of high-density …

Except for aging, carrying the APOE ε4 allele (APOE4) is the most important risk factor for
sporadic Alzheimer's disease. APOE4 carriers may have reduced capacity to recycle lipids …

Abstract Background Blood-based Alzheimer's disease (AD) biomarkers have been
increasingly employed for diagnostic, prognostic, and therapeutic monitoring purposes, due …

This study investigated the diagnostic accuracy of plasma biomarkers—specifically, matrix
metalloproteinase (MMP-9), tissue inhibitor of metalloproteinase (TIMP-1), CD147, and the …